Navigation Links
Diomics Announces Issuance Of U.S. Patents For Novel Biologic Sample DNA Collection Materials For Use In Forensics And Diagnostics
Date:7/14/2014

SAN DIEGO, July 14, 2014 /PRNewswire/ -- Diomics, Inc., provider of X-Swab™, a novel bio-specimen collection material, today announced that the United States Patent and Trademark Office has issued two U.S. Patents held by Diomics covering novel biologic sample collection materials, devices made from them, and methods for their use in forensics and diagnostics.

The primary method of collecting forensic stain materials is by swabbing. Recovery of DNA from a number of commercially-available swabs is not an efficient process. The proprietary technology covered in these patents is applicable for developing an effective tool from material that allows for the efficient capture and release of low template DNA and for increasing yield during PCR.

U.S. Patent 8,685,747 for Porous Materials for Biological Sample Collection, issued 4/1/2014, covers hybrid synthetic materials that capture biologic samples efficiently, and more importantly, readily release analytes, such as DNA, RNA, proteins, lipids, and carbohydrates from collectors that dissolve or disintegrate in extraction media, giving high yields of desired biomolecules with little or no degradation. This allows ready identification of sample donors for forensic purposes with only trace levels of acquired sample. The patent is assigned to the Board of Regents of the University of Arizona, the site of initial studies, licensed exclusively to Diomics, and provided a starting point for R&D that lead to the discovery of proprietary materials that have proven superior in handling of biologic samples.  

U.S. Patent 8,759,075 for Biologic Sample Collection Devices and Methods of Production and Use Thereof, issued 6/24/2014, covers polymeric collection materials, their manufacture and treatment to give desired properties, and their use in collection devices, stemming from R&D work carried out at Diomics. Diomat™, the primary claimed material, has demonstrated superiority to cotton swabs in yielding quality DNA from trace blood samples (0.1 microliter) sufficient to allow STR (short tandem repeat) typing used by law enforcement agencies for donor identification. DNA obtained revealed that samples suffered little or no degradation and were suitable for more extensive sequence analyses. Diomat™ may be configured into sample collection devices for use in forensics and diagnostics applications. X-Swab™, made from Diomat™ was shown to outperform other products used to collect trace blood and saliva samples in trial studies by a leading forensics laboratory. Extracts from X-Swab™ were also found to enhance DNA amplification (PCR), paving the way for broad use of Diomat™-based devices in forensic and diagnostic processes.

"These two patents will provide our products with long-term market exclusivity," said John F. Steel, CEO of Diomics. "Combined with a recent publication in the journal Forensic Science International: Genetics highlighting Diomics novel technology, these patents strengthen our position in forensics and in applications for saliva-based diagnostic in diabetes and oncology."

About Diomics, Inc.

Diomics is focused on life sciences, specifically diagnostics, forensics, integrated DNA analysis and genetic solutions. Our proprietary Diomat™ technology platform has the ability to efficiently pick up biologic materials from a variety of surfaces and release the majority of the DNA from the sample into the solution. The versatile characteristics of Diomat™ lend itself to a variety of product formats, including swabs, films, and fibers. Today based in Carlsbad, California, Diomics has developed numerous products, tools and services for the molecular diagnostic and forensic industries.


'/>"/>
SOURCE Diomics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc.
2. ISSI Announces Fiscal 2014 Third Quarter Conference Call
3. CVS Caremark Corporation Announces Quarterly Dividend
4. Sono-Tek Announces Third Quarter Results
5. Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
6. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
7. Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
8. HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues
9. Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber
10. NuAire announces sales and service of Hitachi Koki centrifuges in North America
11. Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):